Atracurium: Difference between revisions
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
|fdaLIADAdult= | |fdaLIADAdult= | ||
Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation: | * Dosage must be individualized | ||
Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation: | |||
* Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation: | |||
:* Initial | |||
::* 0.4 to 0.5 mg/kg IV bolus | |||
* Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation | |||
:* Maintenance | |||
::* 0.08 to 0.1 mg/kg IV bolus 20 to 45 min after initial dose, then every 15 to 25 min as needed | |||
::* 5 to 9 mcg/kg/min (range 2 to 15 mcg/kg/min) continuous IV infusion after initial dose, upon early evidence of spontaneous recovery; in ICU, 11 to 13 mcg/kg/min (range 4.5 to 29.5 mcg/kg/min) continuous IV infusion | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Atracurium in adult patients. | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Atracurium in adult patients. | ||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Atracurium in adult patients. | |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Atracurium in adult patients. | ||
|fdaLIADPed= | |fdaLIADPed=* Dosage must be individualized | ||
Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation | |||
Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation: | =====Infants (age 1 month to 2 yr)===== | ||
Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation: | * Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation, under halothane anesthesia, | ||
Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation: | :* Initial, 0.3 to 0.4 mg/kg IV | ||
=====Age 2 yr and older===== | |||
* Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation | |||
:* Initial, 0.4 to 0.5 mg/kg IV bolus | |||
=====Age 1 month and older===== | |||
* Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation | |||
:* Maintenance, 0.08 to 0.1 mg/kg IV bolus 20 to 45 min after initial dose, then every 15 to 25 min as needed; children may require maintenance doses more frequently than adults | |||
=====Age 1 month and older===== | |||
* Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation | |||
:* Maintenance, 5 to 9 mcg/kg/min (range 2 to 15 mcg/kg/min) continuous IV infusion after initial dose, upon early evidence of spontaneous recovery | |||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Atracurium in pediatric patients. | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Atracurium in pediatric patients. | ||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Atracurium in pediatric patients. | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Atracurium in pediatric patients. | ||
|alcohol=Alcohol-Atracurium interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |alcohol=Alcohol-Atracurium interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
}} | }} | ||
Revision as of 18:13, 1 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Atracurium is a skeletal muscle relaxant and neuromuscular blocking drugs that is FDA approved for the {{{indicationType}}} of induction of neuromuscular blockade, adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Common adverse reactions include dermatologic: flushing (1% to 29.2% ).
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Dosage must be individualized
- Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation:
- Initial
- 0.4 to 0.5 mg/kg IV bolus
- Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation
- Maintenance
- 0.08 to 0.1 mg/kg IV bolus 20 to 45 min after initial dose, then every 15 to 25 min as needed
- 5 to 9 mcg/kg/min (range 2 to 15 mcg/kg/min) continuous IV infusion after initial dose, upon early evidence of spontaneous recovery; in ICU, 11 to 13 mcg/kg/min (range 4.5 to 29.5 mcg/kg/min) continuous IV infusion
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Atracurium in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Atracurium in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- Dosage must be individualized
Infants (age 1 month to 2 yr)
- Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation, under halothane anesthesia,
- Initial, 0.3 to 0.4 mg/kg IV
Age 2 yr and older
- Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation
- Initial, 0.4 to 0.5 mg/kg IV bolus
Age 1 month and older
- Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation
- Maintenance, 0.08 to 0.1 mg/kg IV bolus 20 to 45 min after initial dose, then every 15 to 25 min as needed; children may require maintenance doses more frequently than adults
Age 1 month and older
- Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation
- Maintenance, 5 to 9 mcg/kg/min (range 2 to 15 mcg/kg/min) continuous IV infusion after initial dose, upon early evidence of spontaneous recovery
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Atracurium in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Atracurium in pediatric patients.
Contraindications
There is limited information regarding Atracurium Contraindications in the drug label.
Warnings
There is limited information regarding Atracurium Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Atracurium Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Atracurium Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Atracurium Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Atracurium in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Atracurium in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Atracurium during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Atracurium in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Atracurium in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Atracurium in geriatric settings.
Gender
There is no FDA guidance on the use of Atracurium with respect to specific gender populations.
Race
There is no FDA guidance on the use of Atracurium with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Atracurium in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Atracurium in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Atracurium in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Atracurium in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Atracurium Administration in the drug label.
Monitoring
There is limited information regarding Atracurium Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Atracurium and IV administrations.
Overdosage
There is limited information regarding Atracurium overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Atracurium Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Atracurium Mechanism of Action in the drug label.
Structure
There is limited information regarding Atracurium Structure in the drug label.
Pharmacodynamics
There is limited information regarding Atracurium Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Atracurium Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Atracurium Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Atracurium Clinical Studies in the drug label.
How Supplied
There is limited information regarding Atracurium How Supplied in the drug label.
Storage
There is limited information regarding Atracurium Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Atracurium |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Atracurium |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Atracurium Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Atracurium interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Atracurium Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Atracurium Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.